138 related articles for article (PubMed ID: 25022661)
1. Ectopic cushing in a patient with medullary thyroid carcinoma: hypercortisolism control and tumor reduction with Sunitinib.
Marques P; Vieira Mda S; Bugalho MJ
Endocrine; 2015 May; 49(1):290-2. PubMed ID: 25022661
[No Abstract] [Full Text] [Related]
2. Sunitinib for the treatment of thyroid cancer.
Gómez-Sáez JM
Expert Opin Investig Drugs; 2016 Nov; 25(11):1345-1352. PubMed ID: 27677828
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib.
Cleary JM; Sadow PM; Randolph GW; Palmer EL; Lynch TP; Nikiforov YE; Wirth LJ
J Clin Oncol; 2010 Aug; 28(23):e390-2. PubMed ID: 20567012
[No Abstract] [Full Text] [Related]
4. Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice.
Díez JJ; Iglesias P; Alonso T; Grande E
Endocrine; 2015 Mar; 48(2):582-8. PubMed ID: 25030550
[TBL] [Abstract][Full Text] [Related]
5. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
Lopergolo A; Nicolini V; Favini E; Dal Bo L; Tortoreto M; Cominetti D; Folini M; Perego P; Castiglioni V; Scanziani E; Borrello MG; Zaffaroni N; Cassinelli G; Lanzi C
J Clin Endocrinol Metab; 2014 Feb; 99(2):498-509. PubMed ID: 24276455
[TBL] [Abstract][Full Text] [Related]
6. Cell Death Induction by the Indirubin Derivative 7BIO and the BH3 Mimetic Drugs ABT-737 and GX15-070 in Medullary Thyroid Carcinoma Cells.
Broecker-Preuss M; Becher-Boveleth N; Mann K
Exp Clin Endocrinol Diabetes; 2016 May; 124(5):324-30. PubMed ID: 26849668
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
Carr LL; Mankoff DA; Goulart BH; Eaton KD; Capell PT; Kell EM; Bauman JE; Martins RG
Clin Cancer Res; 2010 Nov; 16(21):5260-8. PubMed ID: 20847059
[TBL] [Abstract][Full Text] [Related]
8. Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib.
Huang Q; Zhou C; Chen X; Dong B; Chen S; Zhang N; Liu Y; Li A; Yao M; Miao J; Li Q; Wang Z
PLoS One; 2015; 10(10):e0141395. PubMed ID: 26513662
[TBL] [Abstract][Full Text] [Related]
9. Impact of sunitinib on human thyroid cancer cells.
Grosse J; Warnke E; Pohl F; Magnusson NE; Wehland M; Infanger M; Eilles C; Grimm D
Cell Physiol Biochem; 2013; 32(1):154-70. PubMed ID: 23867310
[TBL] [Abstract][Full Text] [Related]
10. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
Ravaud A; de la Fouchardière C; Caron P; Doussau A; Do Cao C; Asselineau J; Rodien P; Pouessel D; Nicolli-Sire P; Klein M; Bournaud-Salinas C; Wemeau JL; Gimbert A; Picat MQ; Pedenon D; Digue L; Daste A; Catargi B; Delord JP
Eur J Cancer; 2017 May; 76():110-117. PubMed ID: 28301826
[TBL] [Abstract][Full Text] [Related]
11. Complete resolution of hypercortisolism with sorafenib in a patient with advanced medullary thyroid carcinoma and ectopic ACTH (adrenocorticotropic hormone) syndrome.
Barroso-Sousa R; Lerario AM; Evangelista J; Papadia C; Lourenço DM; Lin CS; Kulcsar MA; Fragoso MC; Hoff AO
Thyroid; 2014 Jun; 24(6):1062-6. PubMed ID: 24499195
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib in kidney cancer: 10 years of experience and development.
Nassif E; Thibault C; Vano Y; Fournier L; Mauge L; Verkarre V; Timsit MO; Mejean A; Tartour E; Oudard S
Expert Rev Anticancer Ther; 2017 Feb; 17(2):129-142. PubMed ID: 27967249
[TBL] [Abstract][Full Text] [Related]
13. Ectopic adrenocorticotrophic (ACTH) syndrome and small cell carcinoma of the lung-assessment of clinical implications in patients on combination chemotherapy.
Abeloff MD; Trump DL; Baylin SB
Cancer; 1981 Sep; 48(5):1082-7. PubMed ID: 6268276
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.
Fenton MS; Marion KM; Salem AK; Hogen R; Naeim F; Hershman JM
Thyroid; 2010 Sep; 20(9):965-74. PubMed ID: 20629553
[TBL] [Abstract][Full Text] [Related]
15. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
Rosa R; Damiano V; Nappi L; Formisano L; Massari F; Scarpa A; Martignoni G; Bianco R; Tortora G
Br J Cancer; 2013 Aug; 109(3):686-93. PubMed ID: 23839492
[TBL] [Abstract][Full Text] [Related]
16. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
[TBL] [Abstract][Full Text] [Related]
17. Three cases of sporadic medullary thyroid carcinoma in progression treated with sunitinib.
Currás Freixes M; Díaz Pérez JÁ; Casado Herráez A; Ochagavía Cámara S
Endocrinol Nutr; 2014 Jan; 61(1):62-3. PubMed ID: 24125629
[No Abstract] [Full Text] [Related]
18. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
19. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.
Yim KL
Endocrine; 2011 Oct; 40(2):181-6. PubMed ID: 21870172
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib therapy in metastatic papillary thyroid cancer.
Gori S; Foglietta J; Rossi M; Hamzaj A; Stocchi L; Galuppo C; Picece V; Puxeddu E; Furlani L
Tumori; 2013; 99(6):285e-7e. PubMed ID: 24503805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
